Navigation Links
New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Date:12/9/2010

al regions.

LUX-Lung 4 is a phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment.  

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer.  In 2010, approximately 222,250 new cases of lung cancer will be diagnosed in the United States, with 157,300 Americans dying from the disease. NSCLC is the most common form of lung cancer, accounting for about 85 percent of all lung cancers.(3)  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. There is no FDA-approved therapy for patients with advanced lung cancer who have failed chemotherapy and progressed after treatment with an EGFR-TKI.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogene
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... of its Proprietary Technology to Provide Accurate, Fully ... 34th Annual ISCE MeetingSANTA CLARA, Calif., March 31 ... cardiac diagnostic and services company, today announced that ... abstracts and discuss applications for its proprietary technology ...
... published in the Journal of Medicinal Food, ... (1/3 ounce) of "Sun Chlorella A" daily resulted in ... and fasting blood glucose levels.For a 12-week period, 34 ... each morning and evening. Seventeen subjects were healthy; ...
Cached Medicine Technology:NewCardio Leadership to Present Two Abstracts at ISCE Conference 2NewCardio Leadership to Present Two Abstracts at ISCE Conference 3NewCardio Leadership to Present Two Abstracts at ISCE Conference 4First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Learn How Their Employee Health Benefit Plans Stack ... owners and human,resource executives grappling with ways to ... effective found out how their plans,compare to others ... Scott Rappoport, a 25-year veteran of the employee ...
... Band Surgery Performed Each Month in UK, ... LONDON, February 1 Today saw the launch of ... and support to people considering obesity surgery. To,coincide with ... survey reveal,widespread confusion over the causes of obesity in ...
... aren,t getting preventive treatments , , THURSDAY, Jan. 31 ... in hospitals worldwide risk developing dangerous blood clots ... treatments that could prevent the condition, a large ... been recognized to be one of the most ...
... Placement of IVIS Systems -, HOPKINTON, Mass., ... CALP ) today announced the shipment of the ... of 2007.,Introduced in 2000, the IVIS molecular imaging ... biological drug,discovery and development research on small living ...
... House Office of Management and Budget evaluates research at ... using the Program Assessment Rating Tool (PART), a set ... their programs, including whether they can measure and demonstrate ... OMB rates research programs as effective, ineffective, or somewhere ...
... Michael J. Fitzpatrick,executive director of the National ... statement:, A media circus and reckless speculation ... Britney Spears and her family. Professional ethics,require that ... treated,individuals not presume to diagnose them. A person,s ...
Cached Medicine News:Health News:Key to Attracting and Retaining Quality Employees: Benefits 2Health News:Key to Attracting and Retaining Quality Employees: Benefits 3Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 2Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 3Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Caliper Life Sciences Ships 500th IVIS Imaging System 2Health News:Changes needed in how federal government evaluates efficiency of research at EPA, other agencies 2Health News:Britney Spears: Let's Talk About All of Us 2
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: